Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07564102 | dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy | not yet recruiting | Phase 1 / Phase 2 | 30 | Mochida Medical USA, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07584733 | Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma | not yet recruiting | Phase 2 | 50 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07568756 | Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation | not yet recruiting | Phase 2 | 60 | University of California, IrvineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07568236 | A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) | not yet recruiting | Phase 2 | 54 | Chinese University of Hong KongOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4(MITO END-4) | not yet recruiting | Phase 2 | 48 | National Cancer Institute, NaplesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | not yet recruiting | Phase 2 | 230 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497074 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | not yet recruiting | Phase 2 | 78 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 2 | 27 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07489300 | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer(BACON) | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07476677 | Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer(ANDARP) | not yet recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05479045 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | not yet recruiting | Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07457164 | A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer | not yet recruiting | Phase 2 | 40 | Antev Ltd.INDUSTRY | 0 | Mar 12, 2026 | clinicaltrials |
| NCT07460206 | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment(PRELUDE) | not yet recruiting | Phase 2 | 108 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07460245 | Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma(AVESEC) | not yet recruiting | Phase 2 | 144 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07454018 | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07450963 | Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT | not yet recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT07445308 | The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. | not yet recruiting | Phase 1 / Phase 2 | 120 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 0 | Mar 3, 2026 | clinicaltrials |
| NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | not yet recruiting | Phase 2 | 82 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07412171 | NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC(NECTAR) | not yet recruiting | Phase 2 | 40 | Peking University Third HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07406789 | Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).(LUMInova) | not yet recruiting | Phase 2 | 100 | TNC Nutrición Terapéutica S.L.OTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407452 | Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 50 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07401654 | The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression | not yet recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07382713 | Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 43 | Jinhua ZhouOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07374549 | SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 100 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | not yet recruiting | Phase 2 | 87 | Prof. Dr. Remi A. NoutOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer(IMMUNE-SAVE) | not yet recruiting | Phase 2 | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT07370818 | To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer | not yet recruiting | Phase 2 | 81 | Onconic Therapeutics Inc.INDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07363330 | A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 32 | Zhongnan HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07355010 | A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 104 | Qinglei GaoOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07346404 | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma(RUBIKID) | not yet recruiting | Phase 2 | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07348861 | A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 25 | Zheng MinOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07310433 | Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer | not yet recruiting | Phase 2 | 60 | Yung NAOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07300566 | Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial(FORWARD) | not yet recruiting | Phase 2 | 58 | Joelle HelouOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07295132 | RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) | not yet recruiting | Phase 2 | 160 | Asan Medical CenterOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07291557 | PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer | not yet recruiting | Phase 2 | 250 | AHS Cancer Control AlbertaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07282197 | Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 | not yet recruiting | Phase 2 | 40 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07268794 | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer(CONVERT-HB1) | not yet recruiting | Phase 2 | 112 | Fudan UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07244965 | Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials